Precisely, we conjugated a well-established aptamer against AXL (GL21.T), a tyrosine kinase receptor overexpressed in many tumor cells, with miR-148b and generated an axl-148b conjugate able to increase miR-148b expression specifically in AXL+, but not AXL- cells and to reduce cell motility and mammosphere formation in vitro. Here, NTRK1 is linked to neoplasm.